Feb 17, 2026 08:00AM
Dec 2, 2025 08:01AM
Dec 2, 2025 08:00AM
Nov 24, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 6, 2025 08:00AM Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Aug 21, 2025 08:00AM
Aug 14, 2025 08:00AM
Jun 30, 2025 08:00AM
Jun 11, 2025 08:00AM
Jun 3, 2025 08:01AM
Jun 3, 2025 08:00AM
May 15, 2025 08:00AM Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 5, 2025 08:03AM
May 5, 2025 08:00AM
Apr 28, 2025 08:03AM
Apr 28, 2025 08:00AM
Apr 21, 2025 08:00AM
Apr 15, 2025 08:00AM
Mar 27, 2025 08:30AM Chemomab Therapeutics (CMMB) Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial
Mar 27, 2025 08:30AM
Mar 6, 2025 08:00AM
Mar 3, 2025 08:00AM
Feb 19, 2025 07:00AM
Feb 19, 2025 07:00AM
Feb 3, 2025 07:00AM
Dec 3, 2024 07:00AM Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Nov 19, 2024 07:00AM
Nov 14, 2024 07:00AM
Nov 14, 2024 07:00AM
Oct 30, 2024 07:00AM
Oct 15, 2024 07:01AM
Oct 15, 2024 07:00AM
Oct 1, 2024 07:00AM Chemomab Therapeutics to Present at October 2024 Investor Conferences
Aug 21, 2024 07:00AM
Jul 25, 2024 07:01AM
Jul 25, 2024 07:00AM
Jun 18, 2024 07:03AM
Jun 18, 2024 07:00AM
May 9, 2024 07:00AM
Apr 2, 2024 07:00AM Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Mar 25, 2024 07:07AM
Mar 25, 2024 07:06AM
Mar 7, 2024 07:00AM
Feb 20, 2024 07:10AM
Feb 20, 2024 07:00AM
Jan 30, 2024 07:04AM
Jan 30, 2024 07:00AM Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Jan 3, 2024 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All